Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy

Self Cite

The case is a 51-year-old male with obesity, type 2 diabetes (T2D), dyslipidemia, and hypertension. His HbA1c value increased to 8.0%, accompanied by oral semaglutide administration. Glucose variability was exacerbated after that, and then novel imeglimin (Twymeeg) was initiated. HbA1c decreased from 7.4% to 6.7% over 4 months with a 3 kg weight reduction. The case also had low back pain (LBP) and lumbar spinal stenosis (LSS), probably resulting from Metabolic syndrome (Met-S), and had actual experience with a low carbohydrate diet (LCD) in the hospital meals. Four patterns of LCD meals had carbohydrates ranging from 17.8g to 28.0g, with 501-690kcal.

Section: Patients With Lss Have Long-term Impairment In Their Activit...mentioning

confidence: 70%

Actual Meal of Low Carbohydrate Diet (LCD) for Diabetic Patient Treated by Effective Imeglimin (Twymeeg)

Kusumoto,

Bando,

Hayashi

et al. 2023

Self Cite

CT Image of Consolidation and Ground-Glass Opacification (GGO) of COVID-19 in Diabetic Patient

Ogura

Bando

Kato

et al. 2023

Self Cite

The case involves a 70-year-old female with Type 2 Diabetes (T2D) who had been prescribed EquMet (vildagliptin/metformin) and had a stable HbA1c. In August 2022, she tested positive for real-time polymerase chain reaction (RT-PCR) without showing any symptoms. By November 2022, her HbA1c had increased to 7.4%, and a chest CT scan revealed a consolidation lesion in her left lower lung, suggesting post-inflammatory pathology of COVID-19. Imeglimin (Twemeeg) was added to her treatment regimen, and it proved effective, resulting in a 0.9% reduction in HbA1c over 4 months without any gastrointestinal adverse effects (GIAEs). The combined treatment of EquMet and Twymeeg was effective, and the interrelationship between T2D and COVID-19 will be followed up.

Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)

Okada¹,

Bando

Iwatsuki³

et al. 2023

Self Cite

The patient is a 66-year-old female being treated for hypertension. She developed a cerebral vascular accident (CVA) in October 2019, and was subsequently diagnosed with type 2 diabetes (T2D) due to an HbA1c level of 9.8%. She began a low carbohydrate diet (LCD) and started taking oral hypoglycemic agents (OHAs) such as metformin and linagliptin. From July 2021, she occasionally experienced anxiety and palpitations, leading to a diagnosis of reactive depression (adjustment disorder). Despite treatment with etizolam as needed, these symptoms persisted. In December 2022, due to an increase in HbA1c levels to 7.7%, metformin was switched to imeglimin (Twymeeg). By April 2023, her HbA1c had decreased to 6.9%, and she reported a sustained sense of well-being without psychosomatic symptoms.